Directly observed antiretroviral therapy in substance abusers receiving methadone maintenance therapy does not cause increased drug resistance

AIDS Research and Human Retroviruses

Volumn 27, Issue 5, 2011, Pages 535-541

  Brust, James C M ^a   Litwin, Alain H ^a,b   Berg, Karina M ^a,b   Li, Xuan ^a   Heo, Moonseong ^b   Arnsten, Julia H ^a,b  

^a MONTEFIORE MEDICAL CENTER   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; ATAZANAVIR PLUS RITONAVIR; DIDANOSINE; EMTRICITABINE; FOSAMPRENAVIR; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; METHADONE; NEVIRAPINE; STAVUDINE; TENOFOVIR; ZIDOVUDINE;

ADULT; ARTICLE; COMBINATION CHEMOTHERAPY; COMPARATIVE STUDY; DIRECTLY OBSERVED THERAPY; DRUG DEPENDENCE; DRUG DEPENDENCE TREATMENT; DRUG SELF ADMINISTRATION; DRUG SENSITIVITY; FEMALE; GENE MUTATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PHARMACOGENETICS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SUBSTANCE ABUSE; VIRUS LOAD;

ADULT; AMINO ACID SUBSTITUTION; ANALGESICS, OPIOID; ANTI-HIV AGENTS; DIRECTLY OBSERVED THERAPY; DRUG RESISTANCE, VIRAL; FEMALE; HIV; HIV INFECTIONS; HUMANS; MALE; MEDICATION ADHERENCE; METHADONE; MIDDLE AGED; MUTATION, MISSENSE; SUBSTANCE-RELATED DISORDERS; TREATMENT OUTCOME; VIRAL LOAD; VIRAL PROTEINS;

EID: 79955781629     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.2010.0181     Document Type: Article

References (27)

1. May M, Sterne JA, Sabin C, et al.: Prognosis of HIV-1- infected patients up to 5 years after initiation of HAART: Collaborative analysis of prospective studies. AIDS 2007;21: 1185-1197. (Pubitemid 46763289)
2. Walensky RP, Paltiel AD, Losina E, et al.: The survival benefits of AIDS treatment in the United States. J Infect Dis 2006;194:11-19.
3. Braitstein P, Brinkhof MW, Dabis F, et al.: Mortality of HIV- 1-infected patients in the first year of antiretroviral therapy: Comparison between low-income and high-income countries. Lancet 2006;367:817-824.
4. Bangsberg DR, Hecht FM, Charlebois ED, et al.: Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population. AIDS 2000;14: 357-366. (Pubitemid 30182431)
5. Low-Beer S, Yip B, O'Shaughnessy MV, Hogg RS, and Montaner JS: Adherence to triple therapy and viral load response. J Acquir Immune Defic Syndr 2000;23:360-361. (Pubitemid 30327043)
6. Paterson DL, Swindells S, Mohr J, et al.: Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med 2000;133:21-30. (Pubitemid 30432540)
7. Tam LW, Chui CK, Brumme CJ, et al.: The relationship between resistance and adherence in drug-naive individuals initiating HAART is specific to individual drug classes. J Acquir Immune Defic Syndr 2008;49:266-271.
8. Bangsberg DR, Moss AR, and Deeks SG: Paradoxes of adherence and drug resistance to HIV antiretroviral therapy. J Antimicrob Chemother 2004;53:696-699. (Pubitemid 38660267)
9. Gardner EM, Burman WJ, Steiner JF, Anderson PL, and Bangsberg DR: Antiretroviral medication adherence and the development of class-specific antiretroviral resistance. AIDS 2009;23:1035-1046.
10. Ware NC, Wyatt MA, and Tugenberg T: Adherence, stereotyping and unequal HIV treatment for active users of illegal drugs. Soc Sci Med 2005;61:565-576. (Pubitemid 40724602)
11. Ding L, Landon BE, Wilson IB, Wong MD, Shapiro MF, and Cleary PD: Predictors and consequences of negative physician attitudes toward HIV-infected injection drug users. Arch Intern Med 2005;165:618-623. (Pubitemid 40393142)
12. Wood E, Hogg RS, Lima VD, et al.: Highly active antiretroviral therapy and survival in HIV-infected injection drug users. JAMA 2008;300:550-554.
13. Wood E, Hogg RS, Yip B, et al.: Rates of antiretroviral resistance among HIV-infected patients with and without a history of injection drug use. AIDS 2005;19:1189-1195. (Pubitemid 41059260)
14. DiMatteo MR: Variations in patients' adherence to medical recommendations: A quantitative review of 50 years of research. Med Care 2004;42:200-209.
15. Osterberg L and Blaschke T: Adherence to medication. N Engl J Med 2005;353:487-497. (Pubitemid 41127293)
16. Simoni JM, Amico KR, Pearson CR, and Malow R: Strategies for promoting adherence to antiretroviral therapy: A review of the literature. Curr Infect Dis Rep 2008;10:515-521.
17. Maru DS, Kozal MJ, Bruce RD, Springer SA, and Altice FL: Directly administered antiretroviral therapy for HIVinfected drug users does not have an impact on antiretroviral resistance: Results from a randomized controlled trial. J Acquir Immune Defic Syndr 2007;46:555-563. (Pubitemid 350191048)
18. Berg KM, Litwin AH, Li X, Heo M, and Arnsten JH: Directly observed antiretroviral therapy improves adherence and viral load in drug users attending methadone maintenance clinics: A randomized controlled trial. Drug Alcohol Depend 2010; doi: 10.1016/j.drugalcdep.2010.07.025.
19. Berg KM, Mouriz J, Li X, Duggan E, Goldberg U, and Arnsten JH: Rationale, design, and sample characteristics of a randomized controlled trial of directly observed antiretroviral therapy delivered in methadone clinics. Contemp Clin Trials 2009;30:481-489.
20. Johnson VA, Brun-Vezinet F, Clotet B, et al.: Update of the drug resistance mutations in HIV-1: December 2009. Top HIV Med 2009;17:138-145.
21. Bangsberg DR, Acosta EP, Gupta R, et al.: Adherenceresistance relationships for protease and non-nucleoside reverse transcriptase inhibitors explained by virological fitness. AIDS 2006;20:223-231.
22. Lecossier D, Shulman NS, Morand-Joubert L, et al.: Detection of minority populations of HIV-1 expressing the K103N resistance mutation in patients failing nevirapine. J Acquir Immune Defic Syndr 2005;38:37-42. (Pubitemid 40094116)
23. Gross R, Tierney C, Andrade A, et al.: Modified directly observed antiretroviral therapy compared with self-administered therapy in treatment-naive HIV-1-infected patients: A randomized trial. Arch Intern Med 2009;169:1224-1232.
24. Le T, Chiarella J, Simen BB, et al.: Low-abundance HIV drug-resistant viral variants in treatment-experienced persons correlate with historical antiretroviral use. PLoS One 2009; 4:e6079.
25. Ford N, Nachega JB, Engel ME, and Mills EJ: Directly observed antiretroviral therapy: A systematic review and meta-analysis of randomised clinical trials. Lancet 2009; 374:2064-2071.
26. Hart JE, Jeon CY, Ivers LC, et al.: Effect of directly observed therapy for highly active antiretroviral therapy on virologic, immunologic, and adherence outcomes: A meta-analysis and systematic review. J Acquir Immune Defic Syndr 2010; 54:167-179.
27. Sylla L, Bruce RD, Kamarulzaman A, and Altice FL: Integration and co-location of HIV/AIDS, tuberculosis and drug treatment services. Int J Drug Policy 2007;18:306-312. (Pubitemid 47126281)